31 results about "Myocardial infarction diagnosis" patented technology

The invention discloses an acute myocardial infarction diagnosis-oriented biosensor and a preparation method thereof. The sensor comprises a sensor matrix with a field effect tube (FET) structure, and a micro channel system layer, wherein the sensor matrix comprises a silicon-on-insulator (SOI) silicon chip; the surface of the silicon chip is provided with a passivation layer, silicon nanowires of which the surfaces are coupled with monoclonal antibody modified by acute myocardial infarction marker protein, and electrodes; at least local surfaces of the nanowires are exposed in a micro channel in the micro channel system layer; the micro channel is communicated with a sample solution inlet and a sample solution outlet on the micro channel system layer; and the sensor is prepared by a micro-nano processing method. The sensor can detect various marker proteins in serum by an electrical measurement means so as to acquire the degree of myocardial infarction attack. The biosensor can quickly and sensitively detect the myocardial infarction, has high response speed and diagnostic rate, and is suitable for the field of clinical medical detection.

The invention relates to a myocardial infarction diagnostic marker composition and in particular relates to application of miR-1468-5p and miR-892b, which are used as molecular marker compositions, to preparation of a myocardial infarction diagnostic reagent. An existing myocardial infarction diagnostic marker is not sufficient to meet the requirements of clinical precision diagnosis and treatment requirements; expression data of myocardial infarction miRNA (micro Ribonucleic Acid) is obtained based on a high-throughput sequencing method and myocardial infarction related miRNA data of a GEO (Gene Expression Omnibus) database center is combined to carry out bioinformatics analysis and verification; the miR-1468-5p and the miR-892b are selected from candidate miRNA and bioinformatics verification is carried out; a result shows that the miR-1468-5p and the miR-892b are closely related to myocardial infarction. The myocardial infarction diagnostic marker composition can be used for clinical diagnosis and prevention and detection of the myocardial infarction in an independent or combined manner.

The invention relates to a reagent for detecting myocardial infarction and the application of the reagent and particularly relates to a reagent for detecting miR-520c and application of the reagent in preparing reagents for detecting myocardial infarction. Because of specificity, sensitivity and the like, conventional myocardial infarction diagnosis biochemical indexes such as creatine kinase, lactic dehydrogenase and myoglobin are limited in clinical application. On the basis of a high-flux sequencing method, a molecular marker miR-520c tightly associated with myocardial infarction is obtained. The molecular marker and conventional biochemical indexes are supplemented by each other, defects of single detection methods are overcome, and bases are made for precise clinical diagnosis and treatment.

The invention discloses hybridoma cell strains 1-F10 (preservation number: C20122139 and preservation unit: Wuhan University) and 3-H5 (preservation number: C20122140 and preservation unit: Wuhan University), and a monoclonal antibody of an anti-heart-type fatty acid-binding protein (H-FABP) generated by the same. The hybridoma cell strains 1-F10 and 3-H5 are prepared through predicating epitopes in the H-FABP and corresponding antibodies for detection can be secreted; and the subtypes of the monoclonal antibodies of the anti-H-FABP, which are secreted by the hybridoma cell strains 1-F10 and 3-H5, are IgG2a and IgG2b. The antibodies generated by the cell strains 3-H5 and 1-F10 are respectively used as a capturing antibody and a detection antibody, so as to successfully detect the difference of the H-FABP in blood serums of healthy people and myocardial infarction patients, and develop a diagnostic reagent which has good specificity and high accuracy, and can diagnose acute myocardial infarction in early stage.

The invention discloses a detection method in the technical field of biological engineering, in particular a method for diagnosing cardiac troponin I (cTn I) in a semi-quantitative mode by employing double-indicatrix immunochromatography. Acute myocardial infarction (AMI) is a serious disease in a coronary heart disease, is a common emergency among middle-aged and elderly people, and is high in death rate. According to statistics, one third to a half of patients die before being sent to a hospital. In the next 20 years, the AMI is a primary cause for death of the patients around the world. The cTn I is a reliable index which is currently acknowledged and has the highest specificity and the longest duration for myocardial infarction diagnosis. At present, cTn I detection methods which are commonly used in clinic comprise an enzyme-linked immunosorbent assay method and a radioimmunoassay method, which are time-saving, labor-saving, difficult to popularize and high in cost. An immune colloidal gold technology is quickly developed in recent years and can be widely applied to detection of communicable diseases, early pregnancy and cancers. By employing colloidal gold immunochromatography, a quick detection method for the cTn I is established. By adoption of the method, a cTn I gray area of 1 to 5 ng / ml can be subjected to semi-quantitative detection.

The invention discloses an ING1 gene which can serve as a diagnosis tool of myocardial infarction. High-throughput sequencing and QPCR (quantitative polymerase chain reaction) research know that the content of the ING1 gene in blood of a myocardial infarction patient remarkably rises as compared with normal people, western blot experiment results show that the content of ING protein in blood of the myocardial infarction patient remarkably rises as compared with normal people, so that the ING1 gene and the ING protein can serve as molecular markers of diagnosis of the myocardial infarction. Thecontent of the gene or the protein in the blood represents the myocardial infarction, so that a representing method has the advantages that tissue sampling detection is avoided, subject pain is relieved, the representing method can be used for screening of healthy people, and the myocardial infarction is effectively prevented.

The invention relates to a protein marker for myocardial infarction in urine and applications thereof in diagnosis and prognosis, and particularly, relates to applications of identification reagents of following proteins, including antithrombin-III, complement-C3, [alpha]-1-acid glycoprotein 1, serum transferrin, cathepsin Z, and a combination thereof, in preparation of reagents for diagnosis and / or prognosis of the myocardial infarction of patients. Herein, the five proteins have excellent clinical application prospects in the fields of diagnosis of myocardial infarction and detection on diseases status and therapy effects.

The invention discloses a myoglobin detection kit for myocardial infarction diagnosis. The myoglobin detection kit comprises a diagnosis assembly and a blood sampling assembly, the diagnosis assembly is used for displaying a blood detection result; the blood sampling assembly is used for sampling blood from the arm of a user; the diagnosis assembly comprises a shell, test paper and an observation hole; the test paper is fixed in the shell; the observation hole is used for observing test paper detection results; the shell of the blood sampling assembly is fixedly connected with the shell of the diagnosis assembly; the blood sampling assembly comprises a suction cup, a thorn piece, a pressurizing device and a communicating pipe. The bottom edge of the suction cup is fixedly connected with the opening in the bottom face of the blood sampling assembly shell in a sealed mode. And the puncturing sheet is in a triangular sheet shape and is used for puncturing the skin. The kit is convenient for patients to detect by themselves.

The invention provides an lncRNA marker and application thereof in acute myocardial infarction diagnosis. The LncRNA marker is LINC01104, and the expression quantity of the LINC01104 in an acute myocardial infarction patient is lower than that of a normal person. The invention further discloses a fluorescent quantitative PCR kit for detecting acute myocardial infarction. The kit contains a reagentfor measuring expression of the LINC01104. Compared with a traditional biomarker, the LINC01104 marker has better tissue specificity and good stability, and the sensitivity and specificity of acute myocardial infarction diagnosis can be greatly improved.

The invention discloses application of RAE 1 gene or protein as a biomarker for diagnosing myocardial infarction. The content of an RAE1 gene in the blood of a myocardial infarction patient has an obvious difference from normal people, and the myocardial infarction patient and normal crowds can be distinguished according to the difference. The invention also discloses a diagnosis product for the myocardial infarction, and the diagnosis product can be used for realizing a myocardial infarction diagnosis purpose through the detection of the RAE1 gene in the blood.

The invention discloses a myocardial infarction diagnosis related gene. Genes in differential expression between a myocardial infarction patient and a normal person are screened through RNA-seq, and according to large sample QPCR verification, contents of a DOCK10 gene and DOCK10 protein in blood of the myocardial infarction patient are lower than those in blood of the normal person. Therefore, the DOCK10 gene and the DOCK10 protein can be used as biomarkers for diagnosis of myocardial infarction. By research results, a noninvasive method is provided for clinical early diagnosis of myocardialinfarction and suitable for clinical popularization.

The invention discloses a molecular marker for the diagnosis of myocardial infarction. The molecular marker is IVD. By detecting the levels of an IVD gene and an IVD protein in the blood of a subject,whether the subject suffers from myocardial infarction or has the risk of suffering from the myocardial infarction is judged. A product for diagnosing the myocardial infarction through the content ofthe IVD gene or the IVD protein is developed according to the IVD gene and the IVD protein, and the diagnosis product can be popularized and used clinically.

The invention discloses an MAEA gene and an application of an expression product of the MAEA gene to preparation of a diagnostic product. The diagnostic product can be used for diagnosing myocardial infarction. The risk of myocardial infarction of a testee in the future can be judged or the state of myocardial infarction is confirmed by detecting the level of the MAEA gene and the expression product thereof. The diagnostic product takes peripheral blood of the testee as a detection object, and can achieve noninvasive, rapid, sensitive and accurate diagnostic effects.

The invention discloses a KDSR gene which can be used as a molecular marker for early diagnosis of myocardial infarction. Through next-generation sequencing and QPCR method, the KDSR gene is found tohave significant difference in expression in blood of normal persons and myocardial infarction patients, i.e., whether a subject suffers from the myocardial infarction or not can be judged by detecting expression conditions of the KDSR gene in the blood. According to the correlation between the KDSR gene and the myocardial infarction, the invention develops a kit for diagnosing the myocardial infarction; the kit diagnoses the myocardial infarction by detecting the expression of the KDSR gene. The kit disclosed by the invention can be used for the early diagnosis of the myocardial infarction and has a broad clinical application prospect.

The invention discloses a nanotechnology for myocardial infarction diagnosis and a device adopting the nanotechnology. The detection device comprises a sample feeding region, a reagent storage region, a micro-channel and a detection region arranged on the micro-channel, wherein the sample feeding region is provided with a filter membrane for filtering blood cells; a nano magnetic bead-marked anti-human cTnI (cardiac troponin I) monoclonal antibody and a nano fluorescent probe-marked anti-human cTnI monoclonal antibody are stored in the reagent storage region; the reagent storage region is communicated with the detection region through the micro-channel; a magnetic device is arranged below the detection region; a fluorescent detection device is arranged above the detection region. The detection device is used for quantitatively detecting cTnI, and is short in detection time, small in size and convenient to carry.

The invention relates to a magnetic resonance contrast agent. The contrast agent is composed of three parts, namely a single anthraquinone mother nucleus, a connecting arm and an imaging part. The contrast agent can be accumulated on necrotic tissues and infarcted myocardia in necrotic liver, necrotic muscles, and necrotic tissues in tumors and can be used for diagnosing necrosis-related diseasessuch as effect evaluation after tumor treatment and myocardial infarction diagnosis. The contrast agent provided by the invention has relatively high relaxation rate, and standing time on the necrotictissues is relatively long, so that the contrast agent has a wide and stable imaging time window.

The invention relates to application of secretory protein Caspase1 in an early myocardial infarction diagnostic reagent, the amino acid sequence of the secretory protein Caspase1 is shown as SEQ ID NO.1, and during specific detection, after myocardial damage, the content of the secretory protein Caspase1 in peripheral blood is increased. Compared with the prior art, the diagnostic reagent providedby the technical scheme of the invention is beneficial to early diagnosis; the severity degree of myocardial damage can be reflected; the diagnostic reagent can be used as an index for early myocardial infarction diagnosis and prediction, the detection method is simple and easy to operate, the detection sensitivity is good, the system error is small, and the application of the secretory protein Caspasel1 coded by the CASP1 gene in myocardial damage diagnosis reagents can be widely popularized. The kit disclosed by the invention is simple in detection method, low in cost, direct and reliable in detection result and suitable for large-scale screening and diagnosis.

The invention provides an lncRNA marker and application thereof in acute myocardial infarction diagnosis. The LncRNA marker is LINC01104, and the expression quantity of the LINC01104 in an acute myocardial infarction patient is lower than that of a normal person. The invention further discloses a fluorescent quantitative PCR kit for detecting acute myocardial infarction. The kit contains a reagentfor measuring expression of the LINC01104. Compared with a traditional biomarker, the LINC01104 marker has better tissue specificity and good stability, and the sensitivity and specificity of acute myocardial infarction diagnosis can be greatly improved.

A genetic polymorphism associated with myocardial infarction is provided. More particularly, provided are a polynucleotide including a single nucleotide polymorphism (SNP) or a haplotype associated with myocardial infarction, a polynucleotide hybridized with the polynucleotide, a polypeptide encoded by one of the polynucleotides, an antibody bound to the polypeptide, a microarray and a kit including one of the polynucleotides, a myocardial infarction diagnosis method, a SNP detecting method and a method of screening pharmaceutical compositions for myocardial infarction.

The invention relates to application of a specific protein WIPI1 in an early myocardial infarction diagnostic reagent, the amino acid sequence of the specific protein WIPI1 is shown as SEQ ID NO.1, and during specific detection, after myocardial damage, the content of the specific protein WIPI1 in peripheral blood is increased. Compared with the prior art, the diagnostic reagent provided by the technical scheme of the invention is beneficial to early diagnosis, can reflect the severity of myocardial damage, and can be used as an index for early myocardial infarction diagnosis and prediction, and the detection method is relatively simple and easy to operate, has relatively good detection sensitivity, and has relatively small system errors; the application of the specific protein WIPI1 codedby the WIPI1 gene in a myocardial damage diagnosis reagent can be widely popularized; the kit disclosed by the invention is simple in detection method, low in cost, direct and reliable in detection result and suitable for large-scale screening and diagnosis.

The invention belongs to the field of myocardial infarction diagnosis research, and provides application of miR-532-5p and / or miR-766-5p in preparation of an acute myocardial infarction diagnosis product. According to the application disclosed by the invention, the fact that the miR-532-5p and / or the miR-766-5p from the serum exosome can be used as the diagnosis marker for diagnosing the acute myocardial infarction is found for the first time, and the miR-532-5p and / or the miR-766-5p from the serum exosome can be used as the marker for diagnosing the acute myocardial infarction or prognostically judging the acute myocardial infarction, so that the diagnosis of the acute myocardial infarction is more accurate and rapid, and the specificity is high and the sensitivity is good.

The invention relates to a class of magnetic resonance contrast agent, which is composed of three parts: a monoanthraquinone core, a connecting arm and an imaging part. This type of contrast agent can accumulate in necrotic liver, necrotic muscle, necrotic tissue in tumors, and infarcted myocardium, and can be used for the diagnosis of necrosis-related diseases, such as the evaluation of tumor treatment effects and the diagnosis of myocardial infarction. This type of contrast agent has a high relaxation rate; it stays in the necrotic tissue for a long time, and has a wide and stable imaging time window.

A genetic polymorphism associated with myocardial infarction is provided. More particularly, provided are a polynucleotide including a single nucleotide polymorphism (SNP) associated with myocardial infarction, a polynucleotide hybridized with the polynucleotide, a polypeptide encoded by one of the polynucleotides, an antibody bound to the polypeptide, a microarray and a kit including one of the polynucleotides, a myocardial infarction diagnosis method, a SNP detecting method and a method of screening pharmaceutical compositions for myocardial infarction.

The invention relates to application of AKR1B10 to preparation of acute myocardial infarction diagnosis and treatment preparation. The inventor carries out high-throughput sequencing analysis on peripheral blood of acute myocardial infarction patients, after candidate genes are selected, molecule cell experiments verify that AKR1B10 is high in expression in an acute myocardial infarction set, and an AKR1B10 inhibitor can be used for preparing medicine for treating acute myocardial infarction. A new monitoring treatment target point for acute myocardial infarction is provided, and the application has important clinical application value.

The invention discloses a target DUSP6 related to myocardial infarction diagnosis and treatment and application thereof. The invention discloses application of a substance for inhibiting DUSP6 proteinactivity or a substance for inhibiting or silencing Dusp6 gene expression in any one of the following 1) to 11): 1) preparation of a product for treating myocardial infarction; 2) preparation of a product for improving cardiac function after myocardial infarction; 3) preparation of a product for inhibiting ventricular negative reconstruction after myocardial infarction; 4) preparation of a product for inhibiting expansion of infarction area after myocardial infarction; 5) preparation of a product for reducing the death number of myocardial cells in a non-infarction area after myocardial infarction; 6) preparation of a product for up-regulating phosphorylation level of neutrophil ERK; 7) preparation of a product for lowering phosphorylation level of neutrophil p38; 8) preparation of a product for lowering the superoxide release level of the neutrophils; 9) preparation of a product for lowering the degranulation level of the neutrophils; 10) preparation of a product for lowering the tissue killing activity of the neutrophils; and 11) preparation of a product for lowering the heart failure risk.

The invention relates to a protein marker for myocardial infarction in urine and applications thereof in diagnosis and prognosis, and particularly, relates to applications of identification reagents of following proteins, including antithrombin-III, complement-C3, [alpha]-1-acid glycoprotein 1, serum transferrin, cathepsin Z, and a combination thereof, in preparation of reagents for diagnosis and / or prognosis of the myocardial infarction of patients. Herein, the five proteins have excellent clinical application prospects in the fields of diagnosis of myocardial infarction and detection on diseases status and therapy effects.

The invention relates to the technical field of molecular biology and medicine, and discloses a detection method for the rs7832767 locus polymorphism of a myocardial-infarction susceptibility gene and a detection kit.The detection method includes the steps that the genotype of an rs7832767 locus of an SFRP1 gene is detected, wherein the myocardial infarction onset risk of persons with the T genotype in rs7832767 is remarkably higher than that of ordinary persons.The invention further discloses the corresponding detection kit.The detection kit comprises a primer for amplifying the rs7832767 locus.The genotype of the rs7832767 locus is detected with the detection method, persons with the potential myocardial infarction onset risk are screened out, and the aim of preventing myocardial infarction is achieved; the detection method and the detection kit are easy and convenient to operate, short in detection time, low in cost and high in sensitivity and specificity, and a simple and direct new path is provided for diagnosing and treating myocardial infarction.

The invention discloses a chip device for myocardial infarction diagnosis. The chip device is characterized by comprising a sensor main body, wherein a sample injection area, a columnar filtering area, a reagent storage area, a detection area, a micro channel, a magnetic device and an optical detection device are sequentially arranged on the sensor main body along a liquid flow direction; the sample injection area is used for dropwise adding a whole blood sample; the columnar filtering area is used for filtering blood cells and only allows proteins in blood to pass; reagents for a biochemical reaction are arranged in the reagent storage area and comprise a magnetic bead labeled anti-human cTnI monoclonal antibody and a luminescence molecule labeled anti-human cTnI monoclonal antibody; the reagent storage area and the detection area are communicated through the micro channel; the magnetic device is arranged below the sensor main body and is positioned just under the detection area; the optical detection device is arranged above the sensor main body and is positioned just above the detection area. According to the device, quantitative and accurate detection can be realized, the detection time is short, and the device is small in size and portable.

The invention discloses a myocardial infarction differential expression gene and application thereof. A biomarker comprises TEX30 and / or ZNF420. Compared with normal people, TEX30 and ZNF420 show significant difference in myocardial infarction patients, and an ROC curve shows that the TEX30 and ZNF420 have a relatively high AUC value, which prompts that TEX30 and / or ZNF420 can be applied to myocardial infarction diagnosis. The invention provides a product for diagnosing myocardial infarction. The invention also provides a pharmaceutical composition for treating myocardial infarction.